Navigation Links
Colorectal Cancer (CRC) Screening Market for Diagnosis & Treatment 2018 Forecasts in New Research Report at RnRMarketResearch.com
Date:8/12/2013

Dallas, Texas (PRWEB) August 12, 2013

Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. The prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC screening programs, mortality in the developed countries is falling; however incidence continues to rise as a result of diet and increasingly sedentary lifestyles. While historically, colorectal cancer incidence in the developing world is low, in recent years, disease diagnosis rates have dramatically increased, as a result of changing lifestyles, awareness and improved access to medical services. CRC screening can improve survival rates, and reduce the overall cost of patient treatment.

Get a copy of this report @ http://www.rnrmarketresearch.com/medipoint-in-vitro-colorectal-cancer-screening-tests-global-analysis-and-market-forecasts-market-report.html.

Questions Answered in this Report:
Colorectal cancer can be caused by somatic mutations as well as inherited mutations. These mutations lead to changes in the colon that can be detected by detection of bleeding. But many of these mutations can also be detected by genetic and other tests. How quickly will new gene tests be adopted by the CRC screening market?

What are the key differences in CRC screening carried out in different countries, and how will these differences affect adoption of new screening tests?

Existing CRC screening is based on inexpensive, but inaccurate stool analysis tests, or expensive but accurate endoscopies. The first DNA screening tests are expected to come to market in 2014, from Exact Sciences and EpiGenomics. Which new DNA-based screening test will win out?

In-vitro CRC screening is a fast evolving technological area. How will changes in technology affect sales of existing CRC screening tests? Who are the new players in CRC screening? How will patient attitudes affect the In-vitro CRC screening test market?

Major Company Profiles:
1 Abbott Molecular
2 Alere
3 Beckman Coulter
4 Biomarcare Technologies
5 Companion Dx
6 Eiken Chemical
7 Epigenomics
8 Exact Sciences
9 ExiQon
10 Fujirebio (Miraca Holdings)
11 GeneNews
12 GenomicTree
13 Immunostics
14 Kyowa Medex
15 MDx Health (was OncoMethylome)
16 Merck Millipore
17 Metabiomics
18 Mode Diagnostics
19 Oncocyte (Bio Time)
20 Quest Diagnostics
21 R-Biopharm
22 Randox Laboratories
23 Schebo Biotech
24 SciMarket Technologies
25 Siemens Healthcare
26 Signature Diagnostics
27 Sysmex
28 Veda Lab

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=110513.

Browse more reports on Cancer Diagnostics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/diagnostics/in-vitro-diagnostics-ivd/cancer-diagnostics.

About Us:
RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/invitro-colorectal-cancer/screening-market-analysis/prweb11017353.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
2. Study says screening accounts for much of black/white disparity in colorectal cancer
3. Blacks and Hispanics at higher risk for precancerous colorectal polyps
4. Geisel researchers sift through junk to find colorectal cancer clues
5. Blood pressure drugs dont protect against colorectal cancer
6. NIH study finds sigmoidoscopy reduces colorectal cancer rates
7. Colonoscopy screening markedly reduces colorectal cancer incidence and death
8. Surgical patient safety program lowers SSIs by one-third following colorectal operations
9. A recipe for increased colorectal cancer screening rates
10. Gene mutation identifies colorectal cancer patients who live longer with aspirin therapy
11. New electrically-conductive polymer nanoparticles can generate heat to kill colorectal cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology: